Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 26, 2011

Lundbeck Signs Compound Management Agreement with BioFocus

  • Compound Focus, a BioFocus subsidiary,  will manage Lundbeck Research USA's liquid chemical library collection. Compound Focus will distribute screening sets to high-throughput screening centers in the U.S. and Europe.

    Compound Focus houses BioFocus’ compound management facility and is home to sample collections owned by government, academic, and commercial organizations, including the NIH Molecular Libraries Small Molecule Repository. BioFocus has additional compound management agreements with eMolecules, NCI, Procter & Gamble, and TB Alliance.

    “We are pleased to welcome Lundbeck Research USA as a new client,” says Scott Snyder, Compound Focus’ GM. “Compound Focus continues to attract commercial, government, and charitable organizations that see our state of the art automation and compound management experience as a complement to their discovery operations.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »